VANCOUVER, British Columbia, Aug. 04, 2017 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:LAGBF) (Frankfurt:LB6A.F) (the “Company” or “Isodiol”) a global cannabis innovator specializing in the development of pharmaceutical and consumer products announces unaudited July 2017 revenue numbers of its wholly owned subsidiary ISO International LLC of $1,358,787 USD .
Marcos Agramont CEO of Isodiol stated, “We have demonstrated another strong month of top line revenues in what typically is a slow period of the year. Our sales and marketing teams have done an incredible job developing distributor and customer relationships which provide the Company with re-occurring monthly business. In an ultra-competitive industry that is continuously evolving, we continue to establish ourselves as leaders in product quality and service. The Company continues to develop and gain penetration with its Pharmaceutical grade products in Latin America and remains committed to increasing its top line revenues and ultimately increasing its profitability. We continue to develop our infrastructure in Latin America and will begin the due diligence process of expanding into the European and Asian markets in the near future.”
About Isodiol International Inc.
Isodiol International, Inc. is the market leader in pharmaceutical grade cannabis compounds and the industry leader in manufacturing and development of consumer products. Isodiol's nutraceutical division is the pioneer of many firsts for Hemp-derived Cannabinoids, including 99% pure crystalline isolate, micro-encapsulation, and nano technology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, seeking joint ventures and acquisitions to expand its portfolio of brands and subsidiaries and will aggressively continue International expansion into Latin America, Asia and Europe.
Read More